MX379522B - Compuestos de 3,5 difenil-diazol solubles en agua. - Google Patents

Compuestos de 3,5 difenil-diazol solubles en agua.

Info

Publication number
MX379522B
MX379522B MX2018006877A MX2018006877A MX379522B MX 379522 B MX379522 B MX 379522B MX 2018006877 A MX2018006877 A MX 2018006877A MX 2018006877 A MX2018006877 A MX 2018006877A MX 379522 B MX379522 B MX 379522B
Authority
MX
Mexico
Prior art keywords
diphenyl
derivatives
disease
diazole
aqueous solutions
Prior art date
Application number
MX2018006877A
Other languages
English (en)
Spanish (es)
Other versions
MX2018006877A (es
Inventor
Andrei Leonov
Armin Giese
Christian Griesinger
Felix Schmidt
Sergey Ryazanov
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of MX2018006877A publication Critical patent/MX2018006877A/es
Publication of MX379522B publication Critical patent/MX379522B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/11Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018006877A 2015-12-14 2016-12-14 Compuestos de 3,5 difenil-diazol solubles en agua. MX379522B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15199972 2015-12-14
PCT/EP2016/081084 WO2017102893A1 (en) 2015-12-14 2016-12-14 Water-soluble derivatives of 3,5-diphenyl-diazole compounds

Publications (2)

Publication Number Publication Date
MX2018006877A MX2018006877A (es) 2018-09-18
MX379522B true MX379522B (es) 2025-03-10

Family

ID=54850017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006877A MX379522B (es) 2015-12-14 2016-12-14 Compuestos de 3,5 difenil-diazol solubles en agua.

Country Status (21)

Country Link
US (1) US10308671B2 (enExample)
EP (1) EP3390412B1 (enExample)
JP (1) JP6898931B2 (enExample)
KR (1) KR102671166B1 (enExample)
CN (1) CN108473516B (enExample)
AU (1) AU2016372408B2 (enExample)
BR (1) BR112018011994B1 (enExample)
CA (1) CA3008334C (enExample)
CL (1) CL2018001570A1 (enExample)
DK (1) DK3390412T3 (enExample)
ES (1) ES2873510T3 (enExample)
HU (1) HUE054815T2 (enExample)
IL (1) IL260011B (enExample)
MX (1) MX379522B (enExample)
NZ (1) NZ742979A (enExample)
PH (1) PH12018501276A1 (enExample)
PL (1) PL3390412T3 (enExample)
PT (1) PT3390412T (enExample)
RU (1) RU2764131C2 (enExample)
WO (1) WO2017102893A1 (enExample)
ZA (1) ZA201803865B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH713150A2 (fr) * 2016-11-23 2018-05-31 Eta Sa Mft Horlogere Suisse Mécanisme régulateur à résonateur rotatif à guidage flexible entretenu par un échappement libre à ancre.
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
EP4368184A3 (en) 2019-11-19 2024-07-31 Modag GmbH Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
US20250161273A1 (en) * 2022-03-01 2025-05-22 Modag Gmbh Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
CN115337301A (zh) * 2022-07-22 2022-11-15 汕头大学医学院第一附属医院 Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用
CN116399983B (zh) * 2023-06-09 2023-08-15 天津辰欣药物研究有限公司 一种利用gc-ms法检测二叔丁基氯甲基磷酸酯残留量的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
EP2272822A4 (en) * 2008-03-31 2012-01-18 Renascience Co Ltd PLASMINOG ACTIVATOR-1 HEMMER
EP2687513B1 (en) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
JP6069661B2 (ja) * 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
SMT201700306T1 (it) * 2012-06-08 2017-07-18 Theravance Biopharma R&D Ip Llc Inibitori di neprilisina

Also Published As

Publication number Publication date
CN108473516B (zh) 2021-06-18
RU2018125590A (ru) 2020-01-20
CA3008334C (en) 2024-01-02
ZA201803865B (en) 2019-04-24
DK3390412T3 (da) 2021-06-21
RU2764131C2 (ru) 2022-01-13
KR20180089511A (ko) 2018-08-08
PL3390412T3 (pl) 2021-10-25
CA3008334A1 (en) 2017-06-22
PH12018501276A1 (en) 2019-01-28
ES2873510T3 (es) 2021-11-03
IL260011B (en) 2021-12-01
PT3390412T (pt) 2021-06-22
US20180370997A1 (en) 2018-12-27
MX2018006877A (es) 2018-09-18
IL260011A (en) 2018-07-31
CL2018001570A1 (es) 2018-12-28
JP2019501167A (ja) 2019-01-17
EP3390412B1 (en) 2021-04-14
WO2017102893A1 (en) 2017-06-22
KR102671166B1 (ko) 2024-05-31
CN108473516A (zh) 2018-08-31
RU2018125590A3 (enExample) 2020-04-21
AU2016372408A1 (en) 2018-06-21
NZ742979A (en) 2022-05-27
US10308671B2 (en) 2019-06-04
JP6898931B2 (ja) 2021-07-07
BR112018011994A2 (pt) 2018-12-04
BR112018011994B1 (pt) 2022-07-19
EP3390412A1 (en) 2018-10-24
HUE054815T2 (hu) 2021-10-28
AU2016372408B2 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
PH12018501276A1 (en) Water-soluble derivatives of 3,5-diphenyl-diazole compounds
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MX386258B (es) Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas
MX391812B (es) Agonista fxr derivado de esteroides.
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX377305B (es) DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2.
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
EA201391032A1 (ru) Новые гетероциклические производные и их применение в лечении неврологических расстройств
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
CY1123532T1 (el) Αναστολεις του gingipain λυσινης
EA201692300A1 (ru) Производные карбоксамида
MX394882B (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
MX2024013291A (es) Metodos para tratar trastornos neurodegenerativos
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
HK1198514A1 (en) Substituted heterocyclic compounds for disease treatment
SG11202004940VA (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов